ReveraGen and Santhera Announce Funding for FDA Orphan Grant

Rockville, MichiganD, United States, and Pratteln, Switzerland, September 27, 2021 – ReveraGen Biopharma and Santhera Pharmaceuticals (SIX: SANN) announce that ReveraGen has received a USD 1.2 million FDA grant under its “Clinical Studies of Orphan Products in Unmet Rare Disease (R01)” grant program. The grant adds to existing grants from …

Read More »

The partially triggered foreclosures market will record unswerving growth in the period 2021-2031; Development of new anticonvulsant products to strengthen market demand

Seizures are a brain disorder characterized by a sudden and uncontrolled electrical disturbance in the brain. It involves changes in a patient’s behavior, body movements or feelings, and levels of consciousness. Partial seizures, also called focal seizures, are a subtype of seizures characterized by seizures localized to one side of …

Read More »

[COLUMN] Say no to self-medication

A few months ago, Melting Point tackled the issue of self-medication or self-treatment of illnesses by people who have little or no understanding of what is happening to them, and yet engage in guesswork to try to solve their health problems. While it works for a few, it worsens the …

Read More »